Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 22;7(5Part B):708-715.
doi: 10.1016/j.ijwd.2021.07.005. eCollection 2021 Dec.

Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort

Stine Elsgaard  1 , Anna Kathrine Danielsen  1 , Jacob P Thyssen  2 , Mette Deleuran  1 , Christian Vestergaard  1
Affiliations

Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort

Stine Elsgaard et al. Int J Womens Dermatol. .

Abstract

Background: : Systemic immunosuppressive treatments are central in the treatment of severe atopic dermatitis (AD). Yet, comparative data are sparse on the performance of such immunosuppressive treatments in pediatric cohorts with severe AD.

Objective: : This study aimed to examine the drug survival of systemic immunosuppressive treatments in a cohort of children with severe AD.

Methods: : A retrospective pediatric cohort was identified using diagnosis and treatment codes registered in medical charts. In total, 135 cases were identified; of these, 36 were excluded. All information was obtained through examination of clinical records. Drug survival was analyzed with Kaplan-Meier plots, and a log-rank test was used to test for differences in drug survival.

Results: : First-line treatment was primarily methotrexate (MTX; n = 63) and azathioprine (AZA; n = 32). For MTX, the drug survival rates were 69%, 50%, and 18% after 1, 2, and 4 years, respectively, with a median drug survival time of 1.58 years. For AZA, these rates were 63%, 53%, and 21%, respectively, with a median drug survival time of 1.14 years. There was no significant difference in drug survival between the treatments. The main reason for discontinuation was adverse effects (MTX: 25%; AZA: 41%). Despite this, a majority of patients experienced a good effect at the moment of discontinuation or data-lock (MTX: 60%; AZA: 53%), and treatment effect assessed as improvement in sleep quality was highly significant (p = .001). Second-line treatments included MTX (n = 12), AZA (n = 7), and cyclosporine (n = 5). These showed a median drug survival time of 1.8, 0.2, and 0.885 years, respectively.

Conclusion: : MTX and AZA were the dominant first-line treatments prescribed and were safe and equally valuable treatment options for severe childhood AD with similar drug survival outcomes. MTX was the most used second-line treatment.

Keywords: Atopic dermatitis; azathioprine; drug survival; methotrexate; pediatric; systemic immunosuppressive treatment.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig 1
Fig. 1
Flow diagram of the process of exclusion leading to a cohort of 99 eligible cases from a total of 135 identified records.
Fig 2
Fig. 2
Sankey diagram illustrating the sequence of treatments. The columns of treatment boxes represent the first, second, third, and fourth line of treatment. The size of the box and width of the lines are proportional to the number of patients.
Fig 3
Fig. 3
Reported side effects for methotrexate and azathioprine regardless of treatment line, indicated as percent of patients receiving the treatment in one of the treatment lines (i.e., n = 78 for methotrexate; n = 41 for azathioprine).
Fig 4
Fig. 4
Kaplan–Meier curves of drug survival for first-line (azathioprine: n = 63; methotrexate: n = 32; cyclosporine: n = 4) and second-line (azathioprine: n = 5; methotrexate: n = 12; cyclosporine: n = 7; MMF: n = 2) treatments. The event was discontinuation of treatment. Patients who still received treatment were censored.
See this image and copyright information in PMC

References

    1. Andersen YMF, Egeberg A, Skov L, Thyssen JP. Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2019;33(6):1133–1142. - PubMed
    1. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Investigat Dermatol. 2017;137(1):18–25. - PubMed
    1. Cubero JL, Isidoro-García M, Segura N, Pescador DB, Sanz C, Lorente F, et al. Filaggrin gene mutations and new SNPs in asthmatic patients: A cross-sectional study in a Spanish population. Allergy Asthma Clin Immunol. 2016;12:31. - PMC - PubMed
    1. Flohr C, Perkin M, Logan K, Marrs T, Radulovic S, Campbell LE, et al. Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants. J Investigat Dermatol. 2014;134(2):345–350. - PMC - PubMed
    1. Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI. Methotrexate and azathioprine for severe atopic dermatitis: A 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018;178(6):1288–1296. - PubMed